-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Could The CStone Pharmaceuticals (HKG:2616) Ownership Structure Tell Us Something Useful?
Could The CStone Pharmaceuticals (HKG:2616) Ownership Structure Tell Us Something Useful?
A look at the shareholders of CStone Pharmaceuticals (HKG:2616) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. We also tend to see lower insider ownership in companies that were previously publicly owned.
With a market capitalization of HK$5.8b, CStone Pharmaceuticals is a small cap stock, so it might not be well known by many institutional investors. In the chart below, we can see that institutions are noticeable on the share registry. We can zoom in on the different ownership groups, to learn more about CStone Pharmaceuticals.
View our latest analysis for CStone Pharmaceuticals
SEHK:2616 Ownership Breakdown July 19th 2022What Does The Institutional Ownership Tell Us About CStone Pharmaceuticals?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
CStone Pharmaceuticals already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see CStone Pharmaceuticals' historic earnings and revenue below, but keep in mind there's always more to the story.
SEHK:2616 Earnings and Revenue Growth July 19th 2022CStone Pharmaceuticals is not owned by hedge funds. Our data shows that 6 Dimensions Capital, L.P. is the largest shareholder with 25% of shares outstanding. Boyu Capital Consultancy Co., Ltd. is the second largest shareholder owning 12% of common stock, and Pfizer Inc. holds about 9.9% of the company stock. In addition, we found that Ningjun Jiang, the CEO has 2.4% of the shares allocated to their name.
To make our study more interesting, we found that the top 4 shareholders control more than half of the company which implies that this group has considerable sway over the company's decision-making.
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.
Insider Ownership Of CStone Pharmaceuticals
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
Shareholders would probably be interested to learn that insiders own shares in CStone Pharmaceuticals. As individuals, the insiders collectively own HK$173m worth of the HK$5.8b company. This shows at least some alignment. You can click here to see if those insiders have been buying or selling.
General Public Ownership
The general public, who are usually individual investors, hold a 32% stake in CStone Pharmaceuticals. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
Private Equity Ownership
Private equity firms hold a 46% stake in CStone Pharmaceuticals. This suggests they can be influential in key policy decisions. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.
Public Company Ownership
It appears to us that public companies own 9.9% of CStone Pharmaceuticals. It's hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it's worth watching this space for changes in ownership.
Next Steps:
It's always worth thinking about the different groups who own shares in a company. But to understand CStone Pharmaceuticals better, we need to consider many other factors.
Many find it useful to take an in depth look at how a company has performed in the past. You can access this detailed graph of past earnings, revenue and cash flow.
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
看看cStone Pharmicals(HKG: 2616)的股東就能知道哪個集團最強大。機構通常會持有較大公司的股票,我們預計內部人士在較小的公司中佔有相當比例的股票。我們還傾向於看到以前是公有公司的內部所有權較低。
cStone Pharmicals的市值爲58億港元,是一隻小盤股,因此可能不爲許多機構投資者所熟知。在下圖中,我們可以看到機構在股票登記處很明顯。我們可以放大不同的所有權組,以瞭解有關cStone Pharmicals的更多信息。
查看我們對 cStone Pharmicals 的最新分析
聯交所:2616 所有權明細 2022 年 7 月 19 日關於cStone Pharmicals,機構所有權告訴我們甚麼?
許多機構根據近似於當地市場的指數來衡量自己的表現。因此,他們通常會更多地關注主要指數中包含的公司。
cStone Pharmicals已經在股票登記處設立了機構。事實上,他們擁有該公司可觀的股份。這意味着在這些機構工作的分析師已經看過這隻股票,他們很喜歡。但是就像其他人一樣,他們可能錯了。當多家機構擁有一隻股票時,它們總是有處於 “擁擠交易” 的風險。當這樣的交易出錯時,多方可能會競相快速賣出股票。對於沒有增長曆史的公司,這種風險更高。你可以在下面看到cStone Pharmaceuticals的歷史收益和收入,但請記住,故事還有更多。
聯交所:2616 收益和收入增長 2022 年 7 月 19 日cStone Pharmicals不歸對沖基金所有。我們的數據顯示,6 Dimensions Capital, L.P. 是最大的股東,擁有25%的已發行股份。博宇資本諮詢有限公司是第二大股東,擁有普通股12%,輝瑞公司持有約9.9%的公司股份。此外,我們發現首席執行官姜寧軍擁有2.4%的股份分配給了他們的名下。
爲了使我們的研究更有趣,我們發現前四名股東控制着公司一半以上的股份,這意味着該集團對公司的決策具有相當大的影響力。
雖然研究公司的機構所有權可以爲您的研究增加價值,但研究分析師的建議以更深入地瞭解股票的預期表現也是一種好做法。有很多分析師在報道該股,因此可能也值得一看他們的預測。
cStone 製藥的內部所有權
不同國家對內部人士的定義可能略有不同,但董事會成員始終算在內。公司管理層對董事會負責,後者應代表股東的利益。值得注意的是,有時高層管理人員自己也是董事會成員。
當內部所有權表明領導層像公司的真正所有者一樣思考時,內部所有權是積極的。但是,高度的內部所有權也可以賦予公司內部的一小部分人巨大的權力。在某些情況下,這可能是負面的。
股東們可能會有興趣得知內部人士擁有cStone Pharmicals的股份。作爲個人,內部人士共同擁有這家價值58億港元的公司價值1.73億港元的股份。這至少顯示了一些對齊方式。你可以點擊這裏查看那些內部人士是買入還是賣出。
一般公有制
公衆通常是個人投資者,持有cStone Pharmicals32%的股份。雖然這個羣體不一定能做主,但它肯定會對公司的運作方式產生真正的影響。
私募股權所有權
私募股權公司持有cStone Pharmicals46%的股份。這表明他們可以在關鍵政策決策中發揮影響力。這可能會讓一些投資者感到鼓舞,因爲私募股權有時能夠鼓勵有助於市場看到公司價值的策略。或者,這些持有人可能會在投資上市後退出投資。
上市公司所有權
在我們看來,上市公司擁有cStone Pharmicals9.9%的股份。很難肯定地說,但這表明它們將商業利益交織在一起。這可能是一個戰略股份,因此值得關注這個空間的所有權變動。
後續步驟:
總是值得考慮擁有公司股份的不同羣體。但是,爲了更好地瞭解cStone Pharmicals,我們需要考慮許多其他因素。
許多人覺得它很有用 深入瞭解一家公司過去的表現。你可以訪問這個 詳細圖表 過去的收益、收入和現金流。
如果你像我一樣,你可能需要考慮這家公司是會成長還是會萎縮。幸運的是,您可以查看這份免費報告,其中顯示了分析師對其未來的預測。
注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。
對這篇文章有反饋嗎?對內容感到擔憂? 取得聯繫 直接和我們聯繫。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St 的這篇文章本質上是一般性的。 我們僅使用公正的方法提供基於歷史數據和分析師預測的評論,我們的文章無意提供財務建議。 它不構成買入或賣出任何股票的建議,也沒有考慮您的目標或財務狀況。我們的目標是爲您提供由基本面數據驅動的長期重點分析。請注意,我們的分析可能未將最新的價格敏感型公司公告或定性材料考慮在內。簡而言之,華爾街對上述任何股票都沒有頭寸。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧